Promising multiple readouts on its HER2-focused experimental cancer therapy neratinib (PB272) in the year ahead, Puma Biotechnology Inc. unleashed plans for a $190 million follow-on offering to back clinical work and a planned first quarter 2016 new drug application (NDA) for the tyrosine kinase inhibitor.